307730
Tetanus, diphtheria, pertussis vaccination coverage during pregnancy: Evidence from the Pregnancy Risk Assessment and Monitoring System (PRAMS)
Objective: To identify factors associated with Tdap vaccination coverage during pregnancy.
Methods: From September-December 2011, PRAMS collected data on Tdap vaccination from 20 states and New York City. Weighted analysis accounted for the complex survey design and non-response. Bivariate and multivariable logistic regression analyses were used to assess factors associated with Tdap vaccination during pregnancy.
Results: Overall, 42.8% of 7,834 women received a Tdap vaccination (11.7% [n=987] before pregnancy, 6.6% [n=599] during pregnancy, 24.5% [n=2,009] after delivery); 38.1% (n=2,846) respondents did not report receiving vaccination and 19% (n=1,483) did not know their status. Multivariable analyses of those who received vaccination during pregnancy versus not being vaccinated were higher among women who: were Hispanic versus white (adjusted odds ratio [AOR]=2.08; 95% confidence interval [CI]: 1.32-3.28), unmarried versus married (AOR=1.82; 95% CI:1.12-2.96), received timely prenatal care (in the first trimester versus later) (AOR=1.94; 95% CI: 1.10-3.40); and reported other sources of insurance versus private coverage (AOR=2.19; 95% CI 1.20-3.99).
Conclusions: Most recent ACIP recommendations indicate Tdap vaccination for women during each pregnancy. Shortly after being recommended during pregnancy, Tdap vaccination coverage during pregnancy was low; public health efforts are needed to promote the new recommendations for Tdap vaccination during each pregnancy
Learning Areas:
Public health or related educationPublic health or related research
Learning Objectives:
Explain the Tdap coverage among women with live-born infants
Discuss the importance of Tdap vaccination of pregnant women during every pregnancy
Keyword(s): Immunizations, Maternal and Child Health
Qualified on the content I am responsible for because: I am a Senior Scientist at CDC with a PhD in Epidemiology and an MPH. I am the lead epidemiologist with the Pregnancy Risk Assessment Monitoring system working on this topic and also serve on the CDC's Data Resource Center Advisory Committee thus am well-qualified to present on this topic.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.